【摘要】 目的 :观察胰岛素增敏剂罗格列酮的降血糖疗效。方法 :采用双盲双模拟随机对照试验 ,5 5例 2型糖尿病病人分为两组 ,A组给罗格列酮 2 mg口服 ,1次 / d,B组给格华止 85 0 m g口服 ,1次 / d,如 2周后血糖≥ 11.1mmol/ L,则各组加量至 2次 / d,疗程 8周。结果 :罗格列酮治疗后 PBG降低 ,与治疗前比较 ,有显著性差异 (P <0 .0 5 ) ;其降血糖总有效率为 82 .8% ,疗效与格华止相近 (P >0 .0 5 ) ;能降低 FINS,治疗后较治疗前比较 (P <0 .0 5 ) ,明显改善外周组织对胰岛素的敏感性 ,治疗后 IAI增加 ,IRI降低 ,与治疗前相比均有显著性差异 (P <0 .0 5 ) ;治疗副作用轻微 ,主要是胃肠道反应 ,未观察到肝肾功能损害。结论 :胰岛素增敏剂罗格列酮降血糖疗效确切 ,能降低 2型糖尿病人 FINS水平 ,改善外周组织对胰岛素的敏感性 ,副反应轻微 ,未见肝肾功能损害。更多还原

【Abstract】 Objective:Clinical observation of curative effects and side effects of new type insulin increasing sensitivity agent rosiglitazone Method:55 cases of 2 type diabetes mellitus were divided into two groups by double blind double dummy random control method Group A received rosiglitazone 2 mg,qd Group B received metformin 850 mg,qd Two group patients doubled doses for two weeks after treatment if blood sugar ≥11 1 mmol/L Pan course was 8 weeks Results:①Rosiglitazone has indeed curative effect of lowering blood sugar Total utility rate of lowering FBG is 75 86%,and that of lowering PBG is 82 75% Curative effect is similar to that of metformin ②Rosiglitazone can lower level of fasting insulin,increase circumference tissue sensitivity to insulin,and decrease insulin resistance ③Side effects of rosiglitazone treatmeant is slight,and no liver function impair has been observed Conclusion:Rosiglitazone has indeed curative effect of lowering blood sugar,and increases circumference tissue sensitivity to insulin,but no liver function impair has been observed更多还原